Guided Therapeutics (GTHP) Capital Expenditures (2020 - 2022)
Guided Therapeutics' Capital Expenditures history spans 8 years, with the latest figure at $3000.0 for Q4 2022.
- On a quarterly basis, Capital Expenditures fell 25.0% to $3000.0 in Q4 2022 year-over-year; TTM through Sep 2023 was $3000.0, a 90.62% decrease, with the full-year FY2025 number at $2000.0, changed N/A from a year prior.
- Capital Expenditures hit $3000.0 in Q4 2022 for Guided Therapeutics, up from -$3000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for GTHP hit a ceiling of $17000.0 in Q2 2022 and a floor of -$3000.0 in Q3 2022.
- Historically, Capital Expenditures has averaged $5111.1 across 3 years, with a median of $4000.0 in 2021.
- The widest YoY moves for Capital Expenditures: up 1300.0% in 2022, down 160.0% in 2022.
- Tracing GTHP's Capital Expenditures over 3 years: stood at $1000.0 in 2020, then soared by 300.0% to $4000.0 in 2021, then fell by 25.0% to $3000.0 in 2022.
- Business Quant data shows Capital Expenditures for GTHP at $3000.0 in Q4 2022, -$3000.0 in Q3 2022, and $17000.0 in Q2 2022.